Letter: Assessing the prognostic value of agile 3+and agile 4 scores in predicting chronic kidney disease development in patients with metabolic dysfunction-associated steatotic liver disease

被引：0
|
作者：
Qin, Zhenzhi [1 ,2 ]
Xu, Yan [1 ]
机构：
[1] Qingdao Univ, Affiliated Hosp, Dept Nephrol, 16 Jiangsu Rd, Qingdao 266003, Peoples R China
[2] Qingdao Univ, Sch Pharm, Dept Pharmacol, Qingdao, Peoples R China
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2024年 / 60卷 / 11-12期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1111/apt.18287
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
This article is linked to Jung et al paper. To view this article, visit
引用
收藏
页码：1633 / 1634
页数：2
相关论文
共 50 条
  • [1] Agile 3+and Agile 4 scores predict chronic kidney disease development in metabolic dysfunction-associated steatotic liver disease
    Jung, Chan-Young
    Lee, Jung Il
    Ahn, Sang Hoon
    Kim, Seung Up
    Kim, Beom Seok
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (08) : 1051 - 1061
  • [2] Prognostic value of FibroScan based Agile 3+and Agile 4 scores in patients with non-alcoholic fatty liver disease
    Boursier, Jerome
    Canivet, Clemence M.
    Roux, Marine
    Adrien, Lannes
    Fouchard, Isabelle
    Oberti, Frederic
    JOURNAL OF HEPATOLOGY, 2021, 75 : S566 - S566
  • [3] The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-related advanced fibrosis and cirrhosis in the United States population utilizing AGILE 3+and AGILE 4 scores: analysis of the NHANES 2017-2018 cycle
    Alkhouri, Naim
    Almomani, Ashraf
    Le, Phuc
    Payne, Julia Y.
    Asaad, Imad
    Polanco, Prido
    Leff, Phillip
    Kumar, Prabhat
    Noureddin, Mazen
    BMC GASTROENTEROLOGY, 2024, 24 (01)
  • [4] AGILE 3+and AGILE 4 scores for the diagnosis of advanced fibrosis and cirrhosis in patients with non-alcoholic fatty liver disease
    Gjini, Kamela
    Armandi, Angelo
    Caviglia, Gian Paolo
    Rosso, Chiara
    D'Amato, Daphne
    Abdulle, Amina
    Castelnuovo, Gabriele
    del Campo, Nuria Perez Diaz
    Guariglia, Marta
    Bugianesi, Elisabetta
    JOURNAL OF HEPATOLOGY, 2023, 78 : S704 - S704
  • [5] Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence
    Gao, Jingli
    Li, Yuhao
    Zhang, Yijun
    Zhan, Xin
    Tian, Xue
    Li, Junjuan
    Wang, Ru
    He, Yan
    Wang, Anxin
    Wu, Shouling
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (05):
  • [6] Superior diagnostic efficacy of Agile 3+score for diagnosing advanced fibrosis in patients with chronic hepatitis B and concurrent metabolic dysfunction-associated steatotic liver disease
    Rui, Fajuan
    Ni, Wenjing
    Shi, Junping
    Xie, Qing
    Li, Jie
    JOURNAL OF HEPATOLOGY, 2024, 81 (06) : e295 - e297
  • [7] Serial Liver Stiffness Measurement and Fibrosis-4 Scores in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Goyal, Tanvi
    Song, Michael W.
    Suresh, Deepika
    Jasty, Venkata S. J.
    Urias, Esteban
    Wijarnpreecha, Karn
    Wong, Yu Jun
    Chen, Vincent L.
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (11) : 4250 - 4258
  • [8] Diagnostic and prognostic value of plasma lipocalin-2 levels in patients with metabolic dysfunction-associated steatotic liver disease
    ElGhandour, Ahmed Mohamed
    Teama, Nahla Mohamed
    Kamal, Marwa Abdullah
    Nashaat, Ehab Hassan
    Ghani, Amani Mohamed Abdel
    Abdo, Ahmad Abbas
    EGYPTIAN LIVER JOURNAL, 2024, 14 (01)
  • [9] Characterization of gut dysbiosis and intestinal barrier dysfunction in patients with metabolic dysfunction-associated steatotic liver disease and chronic kidney disease: a comparative study
    Thasinas Dissayabutra
    Natthaya Chuaypen
    Pornjira Somnark
    Bootsakorn Boonkaew
    Suwasin Udomkarnjananun
    Piyawan Kittiskulnam
    Pimpisa Charoenchittang
    Pinidphon Prombutara
    Pisit Tangkijvanich
    Scientific Reports, 15 (1)
  • [10] Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Kountouras, Jannis
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (01) : 238 - 239
12345